JP2015514094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514094A5 JP2015514094A5 JP2015503630A JP2015503630A JP2015514094A5 JP 2015514094 A5 JP2015514094 A5 JP 2015514094A5 JP 2015503630 A JP2015503630 A JP 2015503630A JP 2015503630 A JP2015503630 A JP 2015503630A JP 2015514094 A5 JP2015514094 A5 JP 2015514094A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims description 213
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 63
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 claims description 23
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims description 23
- 230000002209 hydrophobic effect Effects 0.000 claims description 20
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 13
- 102000045717 human TLR4 Human genes 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 230000002860 competitive effect Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 238000013389 whole blood assay Methods 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 39
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617164P | 2012-03-29 | 2012-03-29 | |
| US61/617,164 | 2012-03-29 | ||
| PCT/US2013/034543 WO2013149111A2 (en) | 2012-03-29 | 2013-03-29 | Anti-tlr4 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018190726A Division JP2019038816A (ja) | 2012-03-29 | 2018-10-09 | 抗ｔｌｒ４抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514094A JP2015514094A (ja) | 2015-05-18 |
| JP2015514094A5 true JP2015514094A5 (enExample) | 2016-05-19 |
| JP6419064B2 JP6419064B2 (ja) | 2018-11-07 |
Family
ID=48087767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503630A Active JP6419064B2 (ja) | 2012-03-29 | 2013-03-29 | 抗ｔｌｒ４抗体およびその使用 |
| JP2018190726A Pending JP2019038816A (ja) | 2012-03-29 | 2018-10-09 | 抗ｔｌｒ４抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018190726A Pending JP2019038816A (ja) | 2012-03-29 | 2018-10-09 | 抗ｔｌｒ４抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9453076B2 (enExample) |
| EP (1) | EP2831117B1 (enExample) |
| JP (2) | JP6419064B2 (enExample) |
| CN (2) | CN107868128A (enExample) |
| AU (1) | AU2013237929B2 (enExample) |
| CA (1) | CA2869048C (enExample) |
| DK (1) | DK2831117T3 (enExample) |
| ES (1) | ES2651692T3 (enExample) |
| HU (1) | HUE037613T2 (enExample) |
| PL (1) | PL2831117T3 (enExample) |
| WO (1) | WO2013149111A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| EP2173381B1 (en) * | 2007-05-14 | 2013-10-02 | NovImmune SA | Fc receptor-binding polypeptides with modified effector functions |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI654204B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| CA2869048C (en) | 2012-03-29 | 2023-10-17 | Novimmune S.A. | Anti-tlr4 antibodies and uses thereof |
| CA2932787A1 (en) | 2013-12-06 | 2015-06-11 | Novimmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
| CA2941014A1 (en) | 2014-02-28 | 2015-09-03 | Astellas Pharma Inc. | Novel bispecific antibody binding to human tlr2 and human tlr4 |
| CN104013979B (zh) * | 2014-05-28 | 2016-06-15 | 上海纳米技术及应用国家工程研究中心有限公司 | 肠道靶向造影剂的制备方法 |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| SG10201710322VA (en) * | 2014-12-19 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| CN105949319A (zh) * | 2016-04-27 | 2016-09-21 | 柳州市工人医院 | 作为TLR4信号通路抑制剂用于结肠癌治疗的sTLR4和MD2蛋白复合物 |
| BR112019001902A2 (pt) | 2016-08-05 | 2019-07-09 | Chugai Seiyaku Kabushiki Kaisha | composição para profilaxia ou tratamento de doenças relacionadas à il-8 |
| US20210393711A1 (en) | 2018-10-11 | 2021-12-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Bacteria expressing single chain antibodies against toll-like receptors |
| CN115697410A (zh) * | 2020-04-20 | 2023-02-03 | 艾德沙生物科技研究公司 | 用于治疗急性呼吸窘迫综合征的组合物和方法 |
| GB202408008D0 (en) * | 2024-06-05 | 2024-07-17 | Cambridge Entpr Ltd | TLR4 antibody |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| AU681997B2 (en) | 1991-09-05 | 1997-09-18 | University Of Connecticut, The | Targeted delivery of poly- or oligonucleotides to cells |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| US7312320B2 (en) * | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
| DK1711531T3 (da) * | 2003-12-10 | 2012-04-30 | Novimmune Sa | Neutraliserende anti-TLR4/-MD-2-antistoffer og fremgangsmåder til anvendelse deraf |
| US7674884B2 (en) * | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
| DE602005021694D1 (de) * | 2004-12-10 | 2010-07-15 | Novimmune Sa | Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung |
| EP2173381B1 (en) * | 2007-05-14 | 2013-10-02 | NovImmune SA | Fc receptor-binding polypeptides with modified effector functions |
| WO2009138494A2 (en) | 2008-05-15 | 2009-11-19 | Ablynx N.V. | Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors |
| MX2011004674A (es) * | 2008-11-04 | 2011-05-25 | Idera Pharmaceuticals Inc | Modulacion de la expresion del receptor 4 tipo larga distancia por oligonucleotidos antisentido. |
| KR101653030B1 (ko) * | 2010-08-13 | 2016-08-31 | 로슈 글리카트 아게 | 항-테나신-c a２ 항체 및 이의 사용 방법 |
| WO2012096917A1 (en) * | 2011-01-10 | 2012-07-19 | Novimmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
| CA2869048C (en) | 2012-03-29 | 2023-10-17 | Novimmune S.A. | Anti-tlr4 antibodies and uses thereof |
| CN105899231A (zh) * | 2013-10-22 | 2016-08-24 | 诺夫免疫股份有限公司 | 用于在具有升高水平的tlr4配体和其它生物标记的患者中诊断和治疗病症的方法和组合物 |
| CA2932787A1 (en) * | 2013-12-06 | 2015-06-11 | Novimmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
-
2013
- 2013-03-29 CA CA2869048A patent/CA2869048C/en active Active
- 2013-03-29 JP JP2015503630A patent/JP6419064B2/ja active Active
- 2013-03-29 PL PL13715871T patent/PL2831117T3/pl unknown
- 2013-03-29 HU HUE13715871A patent/HUE037613T2/hu unknown
- 2013-03-29 AU AU2013237929A patent/AU2013237929B2/en active Active
- 2013-03-29 US US13/853,158 patent/US9453076B2/en active Active
- 2013-03-29 WO PCT/US2013/034543 patent/WO2013149111A2/en not_active Ceased
- 2013-03-29 CN CN201710750112.2A patent/CN107868128A/zh active Pending
- 2013-03-29 EP EP13715871.3A patent/EP2831117B1/en active Active
- 2013-03-29 DK DK13715871.3T patent/DK2831117T3/en active
- 2013-03-29 ES ES13715871.3T patent/ES2651692T3/es active Active
- 2013-03-29 CN CN201380027744.6A patent/CN104540851B/zh active Active
-
2016
- 2016-09-26 US US15/276,202 patent/US10400044B2/en active Active
-
2018
- 2018-10-09 JP JP2018190726A patent/JP2019038816A/ja active Pending
-
2019
- 2019-07-19 US US16/517,016 patent/US10982004B2/en active Active
-
2021
- 2021-11-15 US US17/526,883 patent/US20220324994A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528476A5 (enExample) | ||
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP2019504032A5 (enExample) | ||
| JP2009518005A5 (enExample) | ||
| JP2020055849A5 (enExample) | ||
| JP2020524661A5 (enExample) | ||
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2010180207A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| JP2019522961A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| JP2015504421A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2022507485A5 (enExample) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2014526898A5 (enExample) | ||
| JP2017505125A5 (enExample) | ||
| FI2897981T3 (fi) | Anti-CD3-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:ta, ja niiden käyttöjä | |
| JP2014512809A5 (enExample) | ||
| RU2016119152A (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2016513682A5 (enExample) | ||
| JP2013517330A5 (enExample) |